在人体感染模型中使用新型8-氨基喹啉抗疟药WR 238605预防恶性疟原虫感染
Prophylaxis of Plasmodium falciparum infection in a human challenge model with WR 238605, a new 8-aminoquinoline antimalarial.
作者信息
Brueckner R P, Coster T, Wesche D L, Shmuklarsky M, Schuster B G
机构信息
Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Washington, DC 20307-5100, USA.
出版信息
Antimicrob Agents Chemother. 1998 May;42(5):1293-4. doi: 10.1128/AAC.42.5.1293.
Abstract
The prophylactic efficacy of WR 238605, a primaquine analog, was studied with a human Plasmodium falciparum challenge model. A single oral dose of 600 mg, administered 1 day prior to challenge, successfully protected three of four subjects. The fourth subject developed mild, oligosymptomatic malaria on day 31, with drug concentrations one-half of those in the protected individuals. WR 238605 appears to be a promising prophylactic drug for P. falciparum malaria.
摘要
用人类恶性疟原虫攻击模型研究了伯氨喹类似物WR 238605的预防效果。在攻击前1天口服600 mg单剂量药物，成功保护了4名受试者中的3名。第四名受试者在第31天出现轻度、症状较少的疟疾，其药物浓度为受保护个体的一半。WR 238605似乎是一种有前景的恶性疟原虫疟疾预防药物。
相似文献
1
Prophylaxis of Plasmodium falciparum infection in a human challenge model with WR 238605, a new 8-aminoquinoline antimalarial.在人体感染模型中使用新型8-氨基喹啉抗疟药WR 238605预防恶性疟原虫感染
Antimicrob Agents Chemother. 1998 May;42(5):1293-4. doi: 10.1128/AAC.42.5.1293.
2
A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria.一种新型伯氨喹类似物，他非诺喹（WR 238605），用于预防恶性疟原虫疟疾。
Clin Infect Dis. 2001 Dec 15;33(12):1968-74. doi: 10.1086/324081. Epub 2001 Nov 7.
3
Antimalarial activity of novel 4-aminoquinolines active against drug resistant strains.新型 4-氨基喹啉类抗疟药对耐药株的抗疟活性。
Bioorg Chem. 2017 Feb;70:74-85. doi: 10.1016/j.bioorg.2016.11.010. Epub 2016 Nov 23.
4
Randomized, Double-Blind, Placebo-Controlled Studies to Assess Safety and Prophylactic Efficacy of Naphthoquine-Azithromycin Combination for Malaria Prophylaxis in Southeast Asia.随机、双盲、安慰剂对照研究评估萘酚喹-阿奇霉素联合用于东南亚疟疾预防的安全性和预防效果。
Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.00793-18. Print 2018 Sep.
5
Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrug-resistant P. falciparum malaria.每月服用他非诺喹预防间日疟原虫和耐多药恶性疟原虫疟疾的疗效。
J Infect Dis. 2004 Oct 15;190(8):1456-63. doi: 10.1086/424468. Epub 2004 Sep 20.
6
A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum.tafenoquine用于每周预防恶性疟原虫的随机、双盲、安慰剂对照、剂量范围试验。
Clin Infect Dis. 2003 Mar 1;36(5):541-9. doi: 10.1086/367542. Epub 2003 Feb 14.
7
Synthesis, characterization, and cellular localization of a fluorescent probe of the antimalarial 8-aminoquinoline primaquine.抗疟药8-氨基喹啉伯氨喹荧光探针的合成、表征及细胞定位
Bioorg Med Chem Lett. 2017 Oct 15;27(20):4597-4600. doi: 10.1016/j.bmcl.2017.09.030. Epub 2017 Sep 14.
8
Ferroquine and artesunate in African adults and children with Plasmodium falciparum malaria: a phase 2, multicentre, randomised, double-blind, dose-ranging, non-inferiority study.铁喹酮和青蒿琥酯治疗非洲成年人和儿童恶性疟原虫疟疾的 2 期、多中心、随机、双盲、剂量范围、非劣效性研究。
Lancet Infect Dis. 2015 Dec;15(12):1409-19. doi: 10.1016/S1473-3099(15)00079-1. Epub 2015 Sep 3.
9
Pharmacokinetics of ferroquine, a novel 4-aminoquinoline, in asymptomatic carriers of Plasmodium falciparum infections.磷酸氟喹在无症状疟原虫感染者中的药代动力学。
Antimicrob Agents Chemother. 2012 Jun;56(6):3165-73. doi: 10.1128/AAC.05359-11. Epub 2012 Mar 19.
10
Prophylactic activity of atovaquone against Plasmodium falciparum in humans.
Am J Trop Med Hyg. 1999 May;60(5):831-6. doi: 10.4269/ajtmh.1999.60.831.
引用本文的文献
1
Pharmacokinetic Models of Tafenoquine: Insights for Optimal Malaria Treatment Strategies.他非诺喹的药代动力学模型：对优化疟疾治疗策略的见解
Pharmaceutics. 2024 Aug 26;16(9):1124. doi: 10.3390/pharmaceutics16091124.
2
Transmission-blocking activity of antimalarials for Plasmodium vivax malaria in Anopheles darlingi.按蚊中抗疟原虫药物对间日疟原虫的阻断作用。
PLoS Negl Trop Dis. 2023 Jun 16;17(6):e0011425. doi: 10.1371/journal.pntd.0011425. eCollection 2023 Jun.
3
Quantification of Tafenoquine and 5,6-Orthoquinone Tafenoquine by UHPLC-MS/MS in Blood, Plasma, and Urine, and Application to a Pharmacokinetic Study.UHPLC-MS/MS 法测定血、血浆和尿中的他非诺喹和 5,6-邻醌他非诺喹及其在药代动力学研究中的应用。
Molecules. 2022 Nov 24;27(23):8186. doi: 10.3390/molecules27238186.
4
Anti-malarial drug effects on parasite dynamics in vivax malaria.抗疟药物对 vivax 疟疾寄生虫动力学的影响。
Malar J. 2021 Mar 21;20(1):161. doi: 10.1186/s12936-021-03700-7.
5
Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.他非诺喹用于预防间日疟原虫疟疾患者复发。
Cochrane Database Syst Rev. 2020 Sep 6;9(9):CD010458. doi: 10.1002/14651858.CD010458.pub3.
6
Liver Enzyme Elevations in Volunteer Infection Studies: Findings and Recommendations.志愿者感染研究中的肝酶升高：发现和建议。
Am J Trop Med Hyg. 2020 Jul;103(1):378-393. doi: 10.4269/ajtmh.19-0846. Epub 2020 Apr 16.
7
8-Aminoquinoline Therapy for Latent Malaria.8-氨基喹啉疗法治疗潜伏疟疾。
Clin Microbiol Rev. 2019 Jul 31;32(4). doi: 10.1128/CMR.00011-19. Print 2019 Sep 18.
8
Clinical utility of tafenoquine in the prevention of relapse of malaria: a review on the mode of action and emerging trial data.他非诺喹在预防疟疾复发中的临床应用：作用模式及新试验数据综述
Infect Drug Resist. 2019 Mar 6;12:553-570. doi: 10.2147/IDR.S151031. eCollection 2019.
9
Tafenoquine for travelers' malaria: evidence, rationale and recommendations. travellers’ malaria: evidence, rationale and recommendations.
J Travel Med. 2018 Jan 1;25(1). doi: 10.1093/jtm/tay110.
10
The blood schizonticidal activity of tafenoquine makes an essential contribution to its prophylactic efficacy in nonimmune subjects at the intended dose (200 mg).tafenoquine的血液裂殖体杀灭活性对其在非免疫人群中按预期剂量（200毫克）发挥预防效果起着至关重要的作用。
Malar J. 2017 May 19;16(1):209. doi: 10.1186/s12936-017-1862-4.
本文引用的文献
1
First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial.新型抗疟药WR 238605的首次人体安全性和药代动力学研究
Am J Trop Med Hyg. 1998 May;58(5):645-9. doi: 10.4269/ajtmh.1998.58.645.
2
Protection of travelers.
Clin Infect Dis. 1997 Aug;25(2):177-84; quiz 185-6. doi: 10.1086/514540.
3
The chemotherapy of rodent malaria. LI. Studies on a new 8-aminoquinoline, WR 238,605.啮齿动物疟疾的化学疗法。II. 关于一种新型8-氨基喹啉WR 238,605的研究。
Ann Trop Med Parasitol. 1993 Dec;87(6):547-52. doi: 10.1080/00034983.1993.11812809.
4
Prophylaxis of Plasmodium falciparum malaria with azithromycin administered to volunteers.
Ann Intern Med. 1995 Nov 15;123(10):771-3. doi: 10.7326/0003-4819-123-10-199511150-00005.
5
Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria.伯氨喹预防恶性疟和间日疟的随机安慰剂对照试验。
Lancet. 1995 Nov 4;346(8984):1190-3. doi: 10.1016/s0140-6736(95)92898-7.
6
Subacute toxicity of primaquine in dogs, monkeys, and rats.伯氨喹对犬、猴和大鼠的亚急性毒性
Bull World Health Organ. 1981;59(3):439-48.
7
Simultaneous modeling of the pharmacokinetics and methemoglobin pharmacodynamics of an 8-aminoquinoline candidate antimalarial (WR 238605).
Pharm Res. 1991 Dec;8(12):1505-10. doi: 10.1023/a:1015842316177.
Zotero 插件